Dr. Clay Siegall Helps Make Seattle Genetics A Leader In Cancer Treatment

Clay B. Siegall, Ph.D. is a trained scientist. And for more than 20 years he has been involved in research to find a cure for cancer. To make more inroads into finding effective treatments for cancer, in 1998 he co-founded Seattle Genetics. The company is built on a foundation of passion for helping cancer patients, rigorous research, scientific innovation and excellent drug development practices. And Dr. Clay Siegall is the president, CEO and board chairman of the company. He is also the chief fundraiser having raised hundreds of millions from public and private sources for the facility.

After completing a bachelor’s at the University of Maryland in Zoology and graduating from George Washington University with a Ph.D. in Genetics, he has worked at some of the leading cancer research organizations in the United States. They include the National Institutes of Health, the National Cancer Institutes and Bristol-Myers Squibb Pharmaceutical Research Institute. The experience he gained there has helped him to make Seattle Genetics into a hotbed for the development of effective cancer treatments.

Behind the leadership of Dr. Siegall Seattle Genetics has taken the lead in developing antibody-drug conjugates. The company also secured FDA approval for ADCETRIS, its first ADC product, in 2011. Since then they’ve collaborated with Takeda Pharmaceutical Company to make ADCETRIS a global brand approved for treating cancer patients in over 60 countries. Seattle Genetics has also developed a diverse pipeline of promising proprietary ADCs. The company also granted strategic licenses to AbbVie, Pfizer, Genentech and GlaxoSmithKline to use its ADC technology.

Seattle Genetics has several internal and external collaborator programs and clinical developments for over 20 ADCs using technology they created. They’ve also raised over $1.2 billion in capital-raising activities including their initial public offering which took place in 2001. Plus licensing activities have generated over $325 million for Seattle Genetics. Dr. Siegall is also on the directorial board of a number of organizations involved in cancer research.

Dr. Siegall has won numerous awards for his work including Entrepreneur of the Year in 2012. He holds i5 patents and has work featured in over 70 publications.